Skip to main content
SpringerLink
Log in

Distilling the Past – Envisioning the Future

  • Chapter
Metastasis of Prostate Cancer

Part of the book series: Cancer Metastasis – Biology and Treatment ((CMBT,volume 10))

  • 677 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 179.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 229.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Penson DF, Albertsen PC. The natural history of prostate cancer. This volume, 2008.

    Google Scholar 

  2. Kessler B, Albertsen P. The natural history of prostate cancer. Urol Clin North Am 2003, 30:219–6.

    PubMed  Google Scholar 

  3. Thompson IM, Goodman PJ, Tangen CM, Scott Lucia M, Miller GJ, Ford LG. The influence of finasteride on the development of prostate cancer. N Eng J Med 2003, 349:215–4.

    CAS  Google Scholar 

  4. Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the united states: Implications of various definitions for abnormal. J Natl Cancer Inst 2005, 97:1132–37.

    PubMed  Google Scholar 

  5. Donovan J, Hamdy F, Neal D, Peters T, Oliver S, Brindle L, et. A. Prostate testing for cancer and treatment (protect) feasibility study. Health Technol Assess 2003, 7:1–88.

    PubMed  CAS  Google Scholar 

  6. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005, 352:1977–84.

    PubMed  CAS  Google Scholar 

  7. Maitland NM. The search for genes which influence prostate cancer metastasis: A moving target. This volume, 2008.

    Google Scholar 

  8. Hendrix MJC, Luo J, Seftor E, Sharma N, Heidger P, Cohen M et al. Epithelial-mesenchymal molecular interactions in prostatic tumor cell plasticity. This volume, 2008.

    Google Scholar 

  9. Davies G, Harrison G, Mason, M. β-Catenin, its binding partners, signalling mechanisms: Implications in prostate cancer. This volume, 2008.

    Google Scholar 

  10. Kuefer R, Hofer MD, Zorn CSM, Engel O, Volkmer BG, Juarez-Brito MA et al. Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer. Br J Cancer 2005, 92:2018–3.

    PubMed  CAS  Google Scholar 

  11. Yegnasubramanian S, Nelson WG. CpG hypermethylation changes during prostate cancer progression and metastasis, pp. 45–79. In: DNA Methylation, Epigenetics and Metastasis. Esteller M, ed., Dordrecht: Springer, 2005.

    Google Scholar 

  12. Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI et al. The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res 2004, 64:825–9.

    PubMed  CAS  Google Scholar 

  13. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 2004, 64:6854–57.

    PubMed  CAS  Google Scholar 

  14. Xing N, Qian J, Bostwick D, Bergstrahl E, Young CY. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate 2001, 48:7–15.

    PubMed  CAS  Google Scholar 

  15. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG. The polycomb group EHZ2 is involved in progression of prostate cancer. Nature 2002, 419:624–9.

    PubMed  CAS  Google Scholar 

  16. Fan L, Pepicelli CV, Dibble CC, Catbagan W, Zarycki JI, Laciak R et al. Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology 2004, 145:3961–70.

    PubMed  CAS  Google Scholar 

  17. Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maltra A et al. Hedgehog signaling in prostate regeneration, neoplasia and metastasis. Nature 2004, 431:707–12.

    PubMed  CAS  Google Scholar 

  18. Lin B, Ferguson C, White JT, Wang S, Vessala R, True LD et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999, 59:4180–84.

    PubMed  CAS  Google Scholar 

  19. Wilson S, Greer B, Hooper J, Zijlstra A, Walker B, Quigley J et al. The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. Biochem J 2005, 388:967–72.

    PubMed  CAS  Google Scholar 

  20. Kufer P, Zippelius A, Lutterbüse R, Mecklenburg I, Enzmann T, Montag A et al. Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: A novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease. Cancer Res 2002, 62:251–61.

    PubMed  CAS  Google Scholar 

  21. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S et al. Phosphorylation of akt (SER473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004, 64:5232–36.

    PubMed  CAS  Google Scholar 

  22. Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol 2004, 4:499–511.

    PubMed  CAS  Google Scholar 

  23. Zheng SL, Augustsson-Bälter K, Chang B, Hedelin M, Li L, Adami H-O et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: Results from the cancer prostate in sweden study. Cancer Res 2004, 64:2918–2.

    PubMed  CAS  Google Scholar 

  24. Li L. Regulation of innate immunity signaling and its connection with human diseases. Curr Drug Targets Inflamm Allergy 2004, 3:81–6.

    PubMed  CAS  Google Scholar 

  25. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005, 65:5009–14.

    PubMed  CAS  Google Scholar 

  26. Eccles SA, Paon L. Breast cancer metastasis: When, where, how. Lancet 2005, 365:1006–07.

    PubMed  Google Scholar 

  27. Singh S, Sadacharan S, Su S, Belldegrun A, Persad S, Singh G. Overexpression of vimentin: Role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res 2003, 63:2306–11.

    PubMed  CAS  Google Scholar 

  28. Martiniello-Wilks R, Dane A, Voeks DJ, Jeyakumar G, Mortensen E, Shaw JM et al. Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. J Gene Med 2004, 6:43–54.

    PubMed  CAS  Google Scholar 

  29. Kacani L, Wurm M, Schennach H, Braun I, Andrle J, Sprinzl GM. Immunosuppressive effects of soluble factors secreted by head and neck squamous cell carcinoma on dendritic cells and T lymphocytes. Oral Oncol 2003, 39:672–9.

    PubMed  CAS  Google Scholar 

  30. Kubsch S, Graulich E, Knop J, Steinbrink K. Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: Association with IL-2- and CTLA-4-dependent G1 arrest of the cell cycle regulated by P27KIP1. Eur J Immunol 2003, 33:1988–97.

    PubMed  CAS  Google Scholar 

  31. Mukherjee P, Ginardi AR, Madsen CS, Tinder TL, Jacobs F, Parker J et al. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment. Glycoconj J 2001, 18:931–42.

    PubMed  CAS  Google Scholar 

  32. Satoh T, Timme TL, Gdor Y, Miles BJ, Amato RJ, Kadmon D et al. Immuno-gene therapy for metastatic prostate cancer. This volume, 2008.

    Google Scholar 

  33. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 1975, 15:617–31.

    PubMed  CAS  Google Scholar 

  34. Jiang WG. Polyunsaturated fatty acid and prostate cancer metastasis. This volume, 2008.

    Google Scholar 

  35. Bidoli R, Talamini R, Bosetti C, Negri E, Maruzzi D, Montella M et al. Macronutrients, fatty acids, cholesterol and prostate cancer risk. Ann Oncol 2005, 16:152–57.

    PubMed  CAS  Google Scholar 

  36. Kelavkar UP. Cohen C. 15-Lipoxygenase-1 expression upregulated, activates insulin-like growth factor-1 receptor in prostate cancer cells. Neoplasia 2004, 6:41–52.

    PubMed  CAS  Google Scholar 

  37. Culig Z. Role of the androgen receptor axis in prostate cancer. Urology 2003, 62:21–6.

    PubMed  Google Scholar 

  38. Bakin RE, Gioeli D, Bissonette EA, Weber MJ. Attenuation of ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res 2003, 63:1975–80.

    PubMed  CAS  Google Scholar 

  39. Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D et al. Castration induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 2003, 63:3575–84.

    PubMed  CAS  Google Scholar 

  40. Lee MS, Igawa T, Yuan TC, Zhang XQ, Lin FF, Lin MF. Erbb-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells. Oncogene 2003, 22:781–96.

    PubMed  CAS  Google Scholar 

  41. Leung HY, Mehta P, Gray LB, Collins AT, Robson CN, Neal DE. Keratinocyte growth factor expression in hormone insensitive prostate cancer. Oncogene 1997, 15:1115–20.

    PubMed  CAS  Google Scholar 

  42. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001, 142:4795–805.

    PubMed  CAS  Google Scholar 

  43. Miyoshi Y, Ishiguro H, Uemura H, Fujinami K, Miyamoto H, Kitamura H et al. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. Prostate 2003, 56:280–6.

    PubMed  CAS  Google Scholar 

  44. Rahman MM, Miyamoto H, Lardy H, Chang C. Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. Proc Natl Acad Sci USA 2003, 100:5124–29.

    PubMed  CAS  Google Scholar 

  45. Lee SO, Lou W, Hou M, deMiguel F, Gerber L, Gao AC. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003, 9:370–76.

    PubMed  CAS  Google Scholar 

  46. Jenster G. The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 1999, 26:407–21.

    PubMed  CAS  Google Scholar 

  47. Yeh S, Lin HK, Kang Thin HYTH, Lin MF, Chang C. From HER2/neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999, 96:5458–63.

    PubMed  CAS  Google Scholar 

  48. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the akt pathway. Cancer Res 2000, 60:6841–45.

    PubMed  CAS  Google Scholar 

  49. Lara PN Jr, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR et al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: Final results from the california cancer consortium screening and phase II trial. Cancer 2004, 100:2125–31.

    PubMed  CAS  Google Scholar 

  50. Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: Scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003, 532:253–68.

    PubMed  CAS  Google Scholar 

  51. de Bono J, Bellmunt J, Droz J, Miller K, Zugmaier G, Sternberg C. An open label, phase II, multicenter, study to evaluate the efficacy, safety of pertuzumab (P) in chemotherapy naïve patients (pts) with hormone refractory prostate cancer (HRPC). J Clin Oncol 2005, 23(Suppl):4609.

    Google Scholar 

  52. Shelley M, Bennett C, Nathan D, Sator O. Hormone treatment for prostate cancer. This volume, 2008.

    Google Scholar 

  53. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer 2000, 88:3009–14.

    PubMed  CAS  Google Scholar 

  54. Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer; initial results of the medical research council trial. Br J Urol 1997, 79:235–46.

    Google Scholar 

  55. Sciarra A, Casale P, Colella D, Di Chiro C, Di Silverio F. Hormone-refractory prostate cancer? Anti-androgen withdrawal and intermittent hormone therapy. Scand J Urol Nephrol 1999, 33:211–6.

    PubMed  CAS  Google Scholar 

  56. Song J, Pang S, Lu Y, Yokoyama KK, Zheng J-Y, Chiu R. Gene silencing in androgen-responsive prostate cancer cells from the tissue-specific prostate-specific antigen promotor. Cancer Res 2004, 64:7661–63.

    PubMed  CAS  Google Scholar 

  57. Kei Kwok W, Ling M-T, Lee T-W, Lau TCM, Zhou C, Zhang X et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005, 65:5153–62.

    Google Scholar 

  58. Newman RM, Zetter BR. Cell cycle regulation. This volume, 2008.

    Google Scholar 

  59. Oudard S, Legrier ME, Boye K, Bras-Goncalves R, De Pinieux G, De Cremoux P et al. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol 2003, 169:1729–34.

    PubMed  CAS  Google Scholar 

  60. Schiller JH. New directions for ZD1839 in the treatment of solid tumors. Semin Oncol 2003, 30:49–55.

    PubMed  CAS  Google Scholar 

  61. Sumitomo M, Tachibana M, Nakashima J, Murai M, Miyajima A, Kimura F et al. An essential role for nuclear factor kappa B in preventing TNF-alpha-induced cell death in prostate cancer cells. J Urol 1999, 161:674–79.

    PubMed  CAS  Google Scholar 

  62. Huang S, Pettaway CA, Bucana CD, Fidler IJ. Blockage of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion and metastasis. Oncogene 2001, 20:4188–97.

    PubMed  CAS  Google Scholar 

  63. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999, 20:345–57.

    PubMed  CAS  Google Scholar 

  64. Hoffman RM. Orthotopic metastatic mouse models of prostate cancer. This volume, 2008.

    Google Scholar 

  65. Clarke N, Fleisch H. The biology of bone metastases from prostate cancer and the role of bisphosphonates. This volume, 2008.

    Google Scholar 

  66. Ayala GE, Dai H, Ittmann M, Li R, Powell M, Frolov A et al. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res 2004, 64:6082–90.

    PubMed  CAS  Google Scholar 

  67. Adis R&D Insight. NF-kappa B inhibitors in development. (file://C:\ WINDOWS\ Temporary%20Internet%20Files\Content.IE5\CKO62R50\NF_Kappa_ inhi_Drugs.htm) Accessed August 31, 2005.

    Google Scholar 

  68. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997, 57:524–31.

    PubMed  CAS  Google Scholar 

  69. Buttyan R, Sawezuk IS, Benson MC, Siegal JD, Olsson CA. Enhanced expression of c-myc protooncogene in high-grade prostate cancers. Prostate 1987, 11:327–7.

    PubMed  CAS  Google Scholar 

  70. Williams K, Fernandez S, Stein X, Ishii K, Love HD, Lau YF et al. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate 2005, 63:369–84.

    PubMed  CAS  Google Scholar 

  71. Blaszczyk N, Masri BA, Mawji NR, Ueda T, McAlinden G, Duncan CP et al. Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin Cancer Res 2004, 10:1860–69.

    PubMed  CAS  Google Scholar 

  72. Garcia-Moreno C, Mendez-Davila C, de La Piedra C, Castro-Errecaborde NA, Traba ML. Human prostatic carcinoma cells produce an increase in the synthesis of interleukin-6 by human osteoblasts. Prostate 2002, 50:241–6.

    PubMed  CAS  Google Scholar 

  73. Masuda H, Fukabori Y, Nakano K, Shimizu N, Yamanaka H. Expression of bone morphogenetic protein-7 (BMP-7) in human prostate. Prostate 2004, 59:101–6.

    PubMed  CAS  Google Scholar 

  74. McAlhany SJ, Ressler SJ, Larsen M, Tuxhorn JA, Yang F, Dang TD et al. Promotion of angiogenesis by PS20 in the differential reactive stroma prostate cancer xenograft model. Cancer Res 2003, 63:5859–65.

    PubMed  CAS  Google Scholar 

  75. Mohammad KS, Guise TA. Mechanisms of osteoblastic metastases: Role of endothelin-1. Clin Orthop Relat Res 2003, S67–74.

    Google Scholar 

  76. Nemeth JA, Cher ML, Zhou Z, Mullins C, Bhagat S, Trikha M. Inhibition of alpha(v)BETA3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis 2003, 20:413–20.

    PubMed  CAS  Google Scholar 

  77. Yonou H, Kanomata N, Goya M, Kamijo T, Yokose T, Hasebe T et al. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res 2003, 63:2096–102.

    PubMed  CAS  Google Scholar 

  78. Ablin RJ, Gonder MJ, eds, Male accessory sexual glands secretions and their antithetical role in immunosurveillance, pp. 271–77. Protides of the Biological Fluids. Oxford: Pergamon Press, Ltd., Vol. 1985.

    Google Scholar 

  79. Wilson MJ, Sinha AA. Matrix degradation in prostate cancer. This volume, 2008.

    Google Scholar 

  80. Szabo KA, Ablin RJ, Singh G. Matrix metalloproteinases and the immune response. Clin Appl Immunol Rev 2004, 4:295–319.

    CAS  Google Scholar 

  81. Ablin RJ. PSA assays. Lancet Oncol 2000, 1:13.

    PubMed  CAS  Google Scholar 

  82. Ablin RJ. A retrospective and prospective overview of prostate-specific antigen. J Cancer Res Clin Oncol 1997, 123:583–94.

    PubMed  CAS  Google Scholar 

  83. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K et al. NF-κB and JNK. J Immunol 2005, 175:1197–205.

    PubMed  CAS  Google Scholar 

  84. Ablin RJ, Bartkus JM, Gonder MJ, Polgar J. Factors contributing to suppression of tumor-host responsiveness, pp. 279–99. In: Human Tumour Markers-Biology and Clinical Applications. Cimino F, Birkmayer CD, Pimentel E, Klavins JV, Salvatore F, eds, Berlin: Walter de Gruyter, 1987.

    Google Scholar 

  85. Ablin RJ, Whyard TC. Immunobiological implications of select bioactive molecules in the prostate with A known and unknown target, pp. 148–72. In: the Prostate as an Endocrine Gland. Farnsworth WE, Ablin RJ, eds, Boca Raton, FL: CRC Press, 1990.

    Google Scholar 

  86. Madsen P, Rasmussen HH, Leffers H, Honore B, Dejgaard K, Olsen E et al. Molecular cloning, occurrence, and expression of a novel partially secreted protein “psoriasin” that is highly up-regulated in psoriatic skin. J Invest Dermatol 1991, 97:701–12.

    PubMed  CAS  Google Scholar 

  87. Ruse M, Lambert A, Robinson N, Ryan D, Shon K-J, Eckert RL. S100A7, S100A10 and S100A11 are transglutaminase substrates. Biochemistry 2001, 40:3167–73.

    PubMed  CAS  Google Scholar 

  88. Davies G, Watkins G, Sanders AJ, Harrison GM, Ablin RJ, Mason MD et al. A hammerhead ribozyme transgene to transglutaminase-4 increases the level of its substrate psoriasin and reduces the invasive capacity of prostate cancer cells in viro (abstract). Proc Am Assoc Cancer Res 2005, 46:5643.

    Google Scholar 

  89. Helbig G, Christopherson IIKW, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD et al. NF-κB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003, 278:21631–38.

    PubMed  CAS  Google Scholar 

  90. Ayra M, Patel HR, McGurk C, Tatoud R, Klocker H, Masters J et al. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastases. J Exp Ther Oncol 2004, 4:291–303.

    Google Scholar 

  91. Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD et al. CXCL12/CXCR4 signaling activates akt-1 and MMP-9 expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12. Prostate 2006, 66:32–48.

    PubMed  CAS  Google Scholar 

  92. Epstein RJ. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer 2004, 4:901–09.

    PubMed  CAS  Google Scholar 

  93. Loberg RD, Fridman Y, Pienta BA, Keller ET, McCauley LK, Taichman RS et al. Detection and isolation of circulating tumor cells in urologic cancers: A review. Neoplasia 2004, 6:302–09.

    PubMed  Google Scholar 

  94. Davies G, Jiang WG, Mason MD. Hepatocyte growth factor/scatter factor and prostate cancer metastasis. This volume, 2008.

    Google Scholar 

  95. Badawi AF. Role of prostaglandin synthesis and cyclooxygenase-2 in prostate cancer and metastasis. This volume, 2008.

    Google Scholar 

  96. Thurairaja R, McFarlane J, Traill Z, Persad R. State-of-the-art approaches to detecting early bone metastasis in prostate cancer. BJU Int 2004, 94:268–71.

    PubMed  Google Scholar 

  97. Mason M, Collaborators. MRCPR4. Of bone metastases from prostate cancer: First results of the MRC PR04 trial (ISCRTN 61384873). Development 2004, 22(Suppl):4511.

    Google Scholar 

  98. Kim S-J, Uehara H, Yazici S, He J, Langley RR, Mathew P et al. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res 2005, 65:3707–25.

    PubMed  CAS  Google Scholar 

  99. Clézardin P, Ebetino FH, Fournier PGJ. Bisphosphonates and cancer-induced bone disease: Beyond their antiresorptive activitivity. Cancer Res 2005, 65:4971–74.

    PubMed  Google Scholar 

  100. Vanchieri C. Vioxx withdrawal alarms cancer prevention researchers. J Natl Cancer Inst 2004, 96:1734–35.

    Article  PubMed  Google Scholar 

  101. Patel MI, Subbaramaiah K, Du B M, Yang P, Newman RA et al. Celecoxib inhibits prostate cancer growth: Evidence of cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005, 11:1999–2007.

    PubMed  CAS  Google Scholar 

  102. Scullin, P, O’Sullivan J, Parker C. Strategies for the implementation of chemotherapy and radiotherapy. This volume 2008.

    Google Scholar 

  103. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005, 65:2825–31.

    PubMed  CAS  Google Scholar 

  104. Henry MD, Wen S, Silva MW, Chandra S, Milton M, Worland PJ. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 2004, 64:7995–8001.

    PubMed  CAS  Google Scholar 

  105. Mukhopadhyay UK, Senderowicz AM, Ferbeyre G. RNA silencing of checkpoint regulators sensitizes P53-defective prostate cancer cells to chemotherapy while sparing normal cells. Cancer Res 2005, 65:2872–81.

    PubMed  CAS  Google Scholar 

  106. Fan Z, Chakravarty P, Alfieri A, Pandita TK, Vikram B, Guha C. Adenovirus-mediated ATM gene transfer sensitizes prostate cancer cells to radiation. Cancer Gene Ther 2000, 7:1307–4.

    PubMed  CAS  Google Scholar 

  107. Ogata T, Teshima T, Kagawa K, Hishikawa Y, Takahashi Y, Kawaguichi A et al. Particle irradiation suppresses metastatic potential of cancer cells. Cancer Res 2005, 65:113–20.

    PubMed  CAS  Google Scholar 

  108. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. J Am Med Assoc 2005, 294:1233–9.

    CAS  Google Scholar 

  109. Milowsky MI, Nanus DM, Kostakoglu I, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of 90y-labeled anti-prostate specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004, 22:2522–31.

    PubMed  CAS  Google Scholar 

  110. Zhao X-Y, Schneider D, Biroc SL, Parry R, Alicke B, Toy P et al. Targeting tomoregulin for radioimmunotherapy of prostate cancer. Cancer Res 2005, 65:2846–53.

    PubMed  CAS  Google Scholar 

  111. Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005, 11:3353–62.

    PubMed  CAS  Google Scholar 

  112. Melnyk O, Zimmerman M, Kim KJ, Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 1999, 161:960–3.

    PubMed  CAS  Google Scholar 

  113. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004, 25:581–611.

    PubMed  CAS  Google Scholar 

  114. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: Identification of a molecular progression switch. Cancer Res 2001, 61:2736–43.

    PubMed  CAS  Google Scholar 

  115. Lissbrant IF, Lissbrant E, Damber J-E, Bergh A. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 2001, 35:437–52.

    PubMed  CAS  Google Scholar 

  116. Halin S, Wikström P, Rudolfsson SH, Stattin P, Doll JA, Crawford SE et al. Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat tumors. Cancer Res 2004, 64:5664–71.

    PubMed  CAS  Google Scholar 

  117. Filleur S, Volz K, Nelius T, Mirochnik Y, Huang H, Zaichuk TA et al. Two functional epitopes of pigment epithelium-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res 2005, 65:5144–51.

    PubMed  CAS  Google Scholar 

  118. Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI et al. Inhibition of angiogenesis by the antiepidermal growth factor antibody IMCLONE C225 in androgen-independent prostate cancer growing orthotopically in nude mouse. Clin Cancer Res 2002, 8:1253–64.

    PubMed  CAS  Google Scholar 

  119. Slovin SF, Kelly WK, Cohen R. Epidermal growth factor receptor (egfr) monoclonal antibody (MOAB) C225 and doxorubicin (DOC) in androgen-independent (AI) prostate cancer (PC): Results of a phase ib/iia study (abstract). Proc Am Soc Clin Oncol 1997, 16:311a.

    Google Scholar 

  120. Rosenthal M, Toner GC, Gurney H. Inhibition of the epidermal growth factor receptor (EGFR) in hormone refractory prostate cancer (HRPC): Initial results of a phase II trial of gefitinib (abstract). Proc Am Soc Clin Oncol 2003, 22:416.

    Google Scholar 

  121. Griffin J. The biology of signal transduction inhibition: Basic science to novel therapies. Semin Oncol 2001, 28:3–8.

    PubMed  CAS  Google Scholar 

  122. Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 2003, 95:458–70.

    PubMed  CAS  Google Scholar 

  123. Tiffany NM, Wersinger EM, Garzotto M, Beer TM. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology 2004, 63:934–39.

    PubMed  CAS  Google Scholar 

  124. Rao KV, Goodin S, Capanna M. A phase II trial of imatinib mesylate in patients with PSA progession after local therapy for prostate cancer. (Abstract). Proc Am Soc Clin Oncol 2003, 22:409.

    Google Scholar 

  125. Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E et al. Progression to androgen independence is delayed by adjuvant treatment with antisense bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999, 5:2891–98.

    PubMed  CAS  Google Scholar 

  126. Kerr C. Second-generation antisense drug for prostate cancer. Lancet Oncol 2004, 5:646.

    PubMed  Google Scholar 

  127. Hershko A, Ciechanover A. The ubiquitin system. Ann Rev Biochem 1998, 67:425–79.

    PubMed  CAS  Google Scholar 

  128. Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: Its molecular target and biochemical activity. Invest New Drugs 1999, 17:361–73.

    PubMed  CAS  Google Scholar 

  129. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D et al. 17-Allylamino-17-demthoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002, 8:986–3.

    PubMed  CAS  Google Scholar 

  130. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW et al. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteasome pathway in prostate cancer cells. Cancer Res 2002, 62:2478–82.

    PubMed  CAS  Google Scholar 

  131. Lokeshwar BL, MG Selzer, Zhu B, Block NL, Golub LM. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int J Cancer 2002, 98:297–309.

    PubMed  CAS  Google Scholar 

  132. Ikezoe T, Yang Y, Saito T, Koeffler HP, Taguichi H. Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-independent human prostate cancer LNCaP cells. Cancer Sci 2004, 95:271–75.

    PubMed  CAS  Google Scholar 

  133. Venkateswaran V, Fleshner NE, Sugar LM, Klotz LH. Antioxidants block prostate cancer in lady transgenic mice. Cancer Res 2004, 64:5891–96.

    PubMed  CAS  Google Scholar 

  134. Tokar EJ, Webber MM. Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells. Clin Exp Metastasis 2005, 22:275–84.

    PubMed  CAS  Google Scholar 

  135. Tokar EJ, Ancrile BB, Ablin RJ, Webber MM. Cholecalciferol (vitamin D3) and the retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) are synergistic for chemoprevention of prostate cancer. J Exp Ther Oncol 2006, 5:323–3.

    PubMed  CAS  Google Scholar 

  136. Guaiquil VH, Vera JC, Golde DW. Mechanism of vitamin C inhibition of cell death induced by oxidative stress in glutathione-depleted HL-60 cells. J Biol Chem 2001, 276:40955–961.

    PubMed  CAS  Google Scholar 

  137. Ablin RJ. Lycopene: A word of caution. Am J Health-Syst Pharm 2005, 62:899.

    PubMed  Google Scholar 

  138. D’Andrea GM. Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin 2005, 55:319–21.

    PubMed  Google Scholar 

  139. Surh YJ. Chemoprevention with dietary phytochemicals. Cancer 2003, 3:768–80.

    PubMed  CAS  Google Scholar 

  140. Li Y, Che M, Bhagat S, Ellis K-L, Kucuk O, Doerge DR et al. Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein. Neoplasia 2004, 6:354–63.

    PubMed  CAS  Google Scholar 

  141. Huang X, Chen S, Xu L, Liu Y, Deb DK, Platanias LC et al. Genistein inhibits P39 map kinase activation, matrix metalloproteinases type 2, and cell invasion in human prostate epithelial cells. Cancer Res 2005, 65:3470–78.

    PubMed  CAS  Google Scholar 

  142. Cha T-L, Qiu L, Chen C-T, Wen Y, Hung M-C. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res 2005, 65:2287–95.

    PubMed  CAS  Google Scholar 

  143. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. TAX 327 investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Eng J Med 2004, 351:1502–2.

    CAS  Google Scholar 

  144. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Eng J Med 2004, 351:1513–20.

    CAS  Google Scholar 

  145. Huggins CB, Stevens RE Jr, Hodges CV. Studies on prostate cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941, 143:209–3.

    Google Scholar 

  146. Ehrlich P. Ueber den jetzigen stand der karzinomforschung. Ned Tijdschr Geneeskd 1909, 5:273–90.

    Google Scholar 

  147. Burnet FM. Cancer: A biological approach. Br Med J 1957, 1:779–86.

    Article  PubMed  CAS  Google Scholar 

  148. Ablin RJ. Immunotherapy for prostatic cancer. Previous and prospective considerations. Oncology 1975, 31:177–202.

    CAS  Google Scholar 

  149. Hawkins LK, Lemonine NR, Kim D. Oncolytic biotherapy: A novel therapeutic platform. Lancet Oncol 2002, 3:17–26.

    PubMed  CAS  Google Scholar 

  150. Kaminski JM, Summers JB, Ward MW, Huber MR, Minev B. Immunotherapy and prostate cancer. Cancer Treat Rev 2003, 29:199–09.

    PubMed  CAS  Google Scholar 

  151. Markiewicz MA, Kast WM. Advances in immunotherapy for prostate cancer. Adv Cancer Res 2003, 87:159–94.

    PubMed  CAS  Google Scholar 

  152. Xue B-H, Zhang Y, Sosman JA, Peace DJ. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate 1997, 30:73–8.

    PubMed  CAS  Google Scholar 

  153. Perambakam S, Xue B-H, Sosman JA, Peace DJ. Induction of TC2 cells with specificity for prostatate-specific antigen from patients with hormone-refractory prostate cancer. Cancer Immunol Immunother 2002, 51:263–70.

    PubMed  CAS  Google Scholar 

  154. Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 2000, 164:5508–14.

    PubMed  CAS  Google Scholar 

  155. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulated CTL responses against metastatic prostate tumors. J Clin Invest 2002, 109:409–17.

    PubMed  CAS  Google Scholar 

  156. Ablin RJ. An appreciation of the concept of cryoimmunology, pp. 136–54. In: Percutaneous Prostate Cryoablation. Onik GM, Rubinsky B, Watson G, Ablin RJ, eds, St. Louis, MO: Quality Medical Publishing, Inc, 1995.

    Google Scholar 

  157. Ablin RJ, Bradley PF. Immunological aspects of cryosurgery, pp. 77–99. In: Cryosurgery of the Maxillofacial Region, Vol. 1. Bradley PF, ed., Boca Raton, FL: CRC Press, 1986.

    Google Scholar 

  158. Ikekawa S, Ishihara K, Tanaka S, Ikeda S. Basic studies of cryochemotherapy in a murine tumor system. Cryobiology 1985, 22:477–83.

    PubMed  CAS  Google Scholar 

  159. Mouraviev V, Prochorov G, Ablin RJ. Cryoimmunochemotherapy for advanced prostate cancer (abstract). Int J Mol Med 2000, 6(Suppl 1):S30.

    Google Scholar 

  160. Veth R, Schreuder B, van Beem H, Pruszczynski M, de Rooy J. Cryosurgery in aggressive, benign, and low-grade malignant tumours. Lancet Oncol 2005, 6:25–34.

    PubMed  Google Scholar 

  161. Callstrom M.,Cryoablation treatment helps diminish pain of bone cancer (Abstract). Society of Interventional Radiology, 30th Annual Meeting. New Orleans, LA. 2005.

    Google Scholar 

  162. Ablin RJ, Soanes WA, Gonder MJ. Prospects for cryo-immunotherapy in cases of metastasizing carcinoma of the prostate. Cryobiology 1971, 8:271–76.

    Google Scholar 

  163. Ablin RJ. The current status and the prospect for cryoimmunotherapy. Low Temp Med 2003, 29:46–9.

    Google Scholar 

  164. Saika T, Kusaka N, Mouraviev V, Satoh T, Kumon H, Timme TL et al. Therapeutic effects of adoptive splenocyte transfer following in situ ADIL-12 gene therapy in a mouse model of prostate cancer. Cancer Gene Ther 2006, 13:91–8.

    PubMed  CAS  Google Scholar 

  165. Pinthus JH, Waks T, Malina V, Kaufman-Francis K, Harmelin A, Aizenberg I et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest 2004, 114:1774–81.

    PubMed  CAS  Google Scholar 

  166. Pinthus JH, Waks T, Kaufman-Francis K, Schindler DG, Harmelin A, Kanety H et al. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res 2003, 63:2470–76.

    PubMed  CAS  Google Scholar 

  167. Eshhar Z. Tumor-specific T bodies: Towards clinical application. Cancer Immunol Immunother 1997, 45:131–6.

    PubMed  CAS  Google Scholar 

  168. Whiteside TL. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 1999, 48:346–52.

    PubMed  CAS  Google Scholar 

  169. Gorter A, Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today 1999, 20:576–82.

    PubMed  CAS  Google Scholar 

  170. Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M, Fishelson Z. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin Exp Immunol 2003, 131:254–63.

    PubMed  CAS  Google Scholar 

  171. NCI Launches Biorepository for Prostate Cancer. NIH News, November 7, 2005. (http://spores.nci.hih.gov/current/prostate/prostate.html) Accessed November 7, 2005.

    Google Scholar 

  172. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011–15.

    PubMed  CAS  Google Scholar 

  173. Botchkina GI, Kim RH, Botchkina IL, Kirshenbaum A, Frischer Z, Adler HL. Noninvasive detection of prostate cancer by quantitative analysis of telomerase activity. Clin Cancer Res 2005, 11:3243–49.

    PubMed  CAS  Google Scholar 

  174. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005, 115:1503–21.

    PubMed  CAS  Google Scholar 

  175. Pipes BL, Ablin RJ. Cancer stem cells revisited. Curr Oncol 2005, 12:134–5.

    Google Scholar 

  176. Bonkhoff H, Remberger K. Differentiation pathways and histogenic aspects of normal and abnormal prostate growth: A stem cell model. Prostate 1996, 28:98–106.

    PubMed  CAS  Google Scholar 

  177. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989, 2:33–50.

    PubMed  CAS  Google Scholar 

  178. Van Leenders G, Schalken JA. Stem cell differentiation within the human prostate epithelium: Implications for prostate carcinogenesis. BJU Intl 2001, 8:35–42.

    Google Scholar 

  179. Collins AT, Habib FK, Maitland NJ, Neal DE. Identification and isolation of human prostate epithelial stem cells based on α 2β 1-integrin expression. J Cell Sci 2001, 114:3865–72.

    PubMed  CAS  Google Scholar 

  180. Schalken JA, Van Leenders G. Cellular and molecular biology of the prostate: Stem cell biology. Urology 2003, 62:11–20.

    PubMed  Google Scholar 

  181. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005, 434:843–50.

    PubMed  CAS  Google Scholar 

  182. Taipale J, Beachy PA. The hedgehog and wnt signalling pathways in cancer. Nature 2001, 411:349–54.

    PubMed  CAS  Google Scholar 

  183. Schmelz M, Moll R, Hesse U, Prasad AR, Gandolfi JA, Bartholdi M, Cress AE. Identification of a stem cell candidate in the normal human prostate gland. Eur J Cell Biol 2005, 84:341–54.

    PubMed  CAS  Google Scholar 

  184. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65:10946–51.

    PubMed  CAS  Google Scholar 

  185. Ablin RJ, Bhatti RA. Tumor-associated immunity in prostate cancer, pp. 183–204. In: Prostatic Cancer, Ablin RJ, ed., New York: Marcel Dekker, Inc, 1981.

    Google Scholar 

  186. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D et al. Autoantibody signatures in prostate cancer. N Eng J Med 2005, 353:1224–35.

    CAS  Google Scholar 

  187. Bhatt RI, Brown MD, Hart CA, Gilmore P, Ramani VA, George NJ et al. Novel method for the isolation and characterization of the putative prostatic stem cell. Cytometry 2003, A: 54:89–99.

    PubMed  Google Scholar 

  188. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105–1.

    PubMed  CAS  Google Scholar 

  189. Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005, 174:3798–807.

    PubMed  CAS  Google Scholar 

  190. Biroccio A, Leonetti C. Telomerase as a new target for the treatment of hormone-refractory prostate cancer. Endocr Relat Cancer 2004, 11:407–21.

    PubMed  CAS  Google Scholar 

  191. He X, Tsang TC, Pipes BP, Ablin RJ, Harris DH. A stem cell fusion model of carcinogenesis. J Exp Ther Oncol 2005, 5:101–9.

    PubMed  CAS  Google Scholar 

  192. Glinsky GV. Death-from-cancer signatures and stem cell contribution to metastatic cancer. Cell Cycle 2005, 4:1171–5.

    PubMed  CAS  Google Scholar 

  193. Pipes BL, Ablin RJ. Cancer: Evasion of stem cell senescence. Submitted.

    Google Scholar 

  194. Yao JL, Madeb R, Bourne P, Lei J, Yang X, Tickoo S et al. Small cell carcinoma of the prostate: An immunohistochemical study. Am J Surg Pathol 2006, 30:705–12.

    PubMed  Google Scholar 

  195. Slovin SF. Neuroendocrine differentiation in prostate cancer: A sheep in wolf’s clothing. Nat Clin Pract Urol 2006, 3:138–44.

    PubMed  Google Scholar 

  196. Papandreou CN, Daliani DD et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002, 20:3072–80.

    PubMed  CAS  Google Scholar 

  197. Zaviacic M. the Human Female Prostate. From Vestigial Skene’s Paraurethral Glands and Ducts to Woman’s Functional Prostate. Bratislava: Slovak Academic Press, 1999. 171 p.

    Google Scholar 

  198. Zaviacic M, Ablin RJ. The female prostate and prostate-specific antigen. Immunohistochemical localization, implications of this prostate marker in woman and reasons for using the term “prostate” in the human female. Histol Histopathol 2000, 15:131–42.

    PubMed  CAS  Google Scholar 

  199. Sloboda J, Zaviacic M, Jakubovsky J, Hammar E, Johnson J. Metastasizing adenocarcioma of the female prostate (skene’s paraurethral glands). Pathol Res Pract 1998, 194:129–36.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunobiology, University of Arizona College of Medicine and the Arizona Cancer Center, Tucson, AZ, USA

    Richard J. Ablin

  2. Section of Oncology and Palliative Medicine, University of Wales College of Medicine, Velindre Hospital, Cardiff, Wales, UK

    Malcolm D. Mason

Authors
  1. Richard J. Ablin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Malcolm D. Mason
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Arizona College of Medicine, and the Arizona Cancer Center, Tucson, AZ, U.S.A

    Richard J. Ablin

  2. University of Cardiff, U.K

    Malcolm D. Mason

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Ablin, R.J., Mason, M.D. (2008). Distilling the Past – Envisioning the Future. In: Ablin, R.J., Mason, M.D. (eds) Metastasis of Prostate Cancer. Cancer Metastasis – Biology and Treatment, vol 10. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-5847-9_16

Download citation

Publish with us

Policies and ethics

Search

Navigation